Tumor-Activated Carrier-Free Dual-Prodrug Nanoassemblies for Synergistic Chemo-Immunotherapy
Authors:
- 21 September 2026
- journal article
- Published by American Chemical Society (ACS) in Nano Letters
- Vol. 26 (38) , 12750-12760
Abstract
Chemo-immunotherapy is limited by the poor bioavailability, nonspecific distribution, and systemic toxicity of free drugs. Here, we develop a reactive oxygen species (ROS)-responsive prodrug strategy by conjugating paclitaxel (PTX) and the TLR7/8 agonist resiquimod (R848) with a phenylboronic ester (PBE) moiety to generate two ROS-activatable prodrugs, PTX–PBE and R848–PBE. These prodrugs spontaneously coassemble into carrier-free nanoparticles (PR NPs) with ultrahigh loading efficiency and tunable drug ratios. PBE modification improves systemic stability while enabling ROS-triggered drug release in the tumor microenvironment, allowing PTX-mediated immunogenic cell death and R848-mediated innate immune activation. In colorectal cancer models, PR NPs suppress tumor growth, reduce systemic toxicity, and remodel the tumor immune microenvironment by promoting antitumor immune responses. This prodrug engineering strategy provides a high-loading, activatable, and carrier-free platform for chemo-immunotherapy with potential for cancer treatment.Keywords
Funding Information
- Health Commission of Jilin Province (2025SCZ59)
- Ministry of Science and Technology of the People's Republic of China (2025YFE0114200)
- Jilin University (2022JBGS04)
- Jilin University (2025-CJUH-XTCX2.0-008)
- Jilin University (2026B24)
- Jilin University (CJUH-SINH009)
- Jilin University (Collaborative Innovation Project (Version 1.0) of)
- Department of Science and Technology of Jilin Province (20240501002GH)
- Department of Science and Technology of Jilin Province (20260101020JJ)
- Department of Science and Technology of Jilin Province (CBS2026005)
- Department of Science and Technology of Jilin Province (YDZJ202102CXJD020)
- Department of Science and Technology of Jilin Province (YDZJ202602CXJD007)
- Jilin Province Development and Reform Commission (2021C023)
- Education Department of Jilin Province (JJKH20250194BS)
- National Natural Science Foundation of China (NSFC) (32401174)
- National Natural Science Foundation of China (NSFC) (32571686)
- National Natural Science Foundation of China (NSFC) (82572298)
- National Natural Science Foundation of China (NSFC) (U24A20477)
- Science and Technology Department, Henan Province (2024001)
This publication has 42 references indexed in Scilit:
- Phenylboronic acid modification and small-molecule assembly to enhance the safety of resiquimod and its synergistic anti-tumor efficacy with paclitaxelColloids and Surfaces B: Biointerfaces, 2026
- The progress and perspective of nanomedicine in modulating the tumor immune microenvironmentActa Pharmaceutica Sinica B, 2025
- ROS-responsive resiquimod prodrug nanoparticles for macrophage reprogramming and enhanced immune checkpoint inhibitor therapy in bladder cancerBiomaterials, 2025
- Self-assembled nanoplatforms for cancer immunotherapy: Principles, progress and perspectivesActa Pharmaceutica Sinica B, 2025
- Evoking Simultaneous Ferroptosis and Apoptosis by a Dual‐Locked Platinum (IV) Prodrug for Synergistic Chemo‐immunotherapyAngewandte Chemie International Edition, 2025
- Recent advances in reactive oxygen species (ROS)-responsive drug delivery systems for photodynamic therapy of cancerActa Pharmaceutica Sinica B, 2024
- Liposomes-enabled cancer chemoimmunotherapyBiomaterials, 2024
- Molecular Masking of Synthetic Immunomodulator Evokes Antitumor Immunity With Reduced Immune Tolerance and Systemic Toxicity by Temporal Activity Recovery and Sustained StimulationAdvanced Materials, 2023
- Self-assembled nanoformulations of paclitaxel for enhanced cancer theranosticsActa Pharmaceutica Sinica B, 2023
- Immunogenic-cell-killing and immunosuppression-inhibiting nanomedicineBioactive Materials, 2021